CIK 0001590877 · Non-accelerated filer<br>Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 471851754
- Phone
- 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-03-31 | Vasista Vittal Chief Financial Officer | Option exercise | +10,000 | $0.85 | $9K | 220,215 |
| 2020-03-31 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −10,000 | 74,900 | ||
| 2020-02-11 | Simpson Curran SVP, Product Development & CTO | Option exercise | +6,633 | $22.00 | $146K | 16,512 |
| 2020-02-11 | Simpson Curran SVP, Product Development & CTO | Sale | −8,872 | $50.13 | $445K | 7,640 |
| 2020-02-11 | Simpson Curran SVP, Product Development & CTO | Sale | −3,692 | $51.37 | $190K | 3,948 |
| 2020-02-11 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −6,633 | 0 | ||
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise | +4,253 | $19.50 | $83K | 26,901 |
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise | +14,928 | $22.00 | $328K | 41,829 |
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise | +12,479 | $35.80 | $447K | 54,308 |
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Sale | −44,429 | $50.22 | $2.2M | 9,879 |
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −12,479 | 27,500 | ||
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −14,928 | 6,633 | ||
| 2020-02-10 | Simpson Curran SVP, Product Development & CTO | Option exercise · Stock Option (Right to Buy) | −4,253 | 8,125 | ||
| 2020-02-10 | Vasista Vittal Chief Financial Officer | Option exercise | +3,000 | $13.09 | $39K | 225,021 |
| 2020-02-10 | Vasista Vittal Chief Financial Officer | Sale | −677 | $49.05 | $33K | 224,344 |
| 2020-02-10 | Vasista Vittal Chief Financial Officer | Sale | −14,129 | $50.12 | $708K | 210,215 |
| 2020-02-10 | Vasista Vittal Chief Financial Officer | Option exercise · Employee Stock Option (Right to Buy) | −3,000 | 26,374 | ||
| 2020-02-10 | HAYDEN DONALD J JR Director | Option exercise | +24,800 | $0.85 | $21K | 24,800 |
| 2020-02-10 | HAYDEN DONALD J JR Director | Sale | −24,800 | $50.11 | $1.2M | 0 |
| 2020-02-10 | HAYDEN DONALD J JR Director | Option exercise · Stock Option (Right to Buy) | −24,800 | 129,100 |
Page 23 of 25 · 494 trades